Article (Scientific journals)
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Ketterer, Nicolas; Coiffier, Bertrand B.; Thieblemont, Catherine et al.
2013In Annals of Oncology, 24/n°4, p. 1032-1037
Peer Reviewed verified by ORBi
 

Files


Full Text
Ann Oncol.- Phase III study of ACVBP... 2012.pdf
Publisher postprint (397.26 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Chemotherapy; Localized lymphoma; Low risk; Rituximab; Treatment
Abstract :
[en] Background The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparaison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for Young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which évaluâtes the role of rituximab combined with ACVBP (R- ACVBP) in these patients. Patients and methods untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. Results a total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P=0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P=0.0205). Overall survival did not differ between the two groups with a 3-year estimâtes of 98% and 97%, respectively (P=0.686). Conclusion in Young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly Superior to ACVBP plus consolidation alone.
Disciplines :
Hematology
Author, co-author :
Ketterer, Nicolas
Coiffier, Bertrand B.
Thieblemont, Catherine
Fermé, Christophe
Brière, Josette F.
Casasnovas, Olivier
Bologna, Serge
Christian, Bernard
Connerotte, Thierry
Récher, C.
Bordessoule, Dominique
Fruchart, Christophe
Delarue, Richard
Bonnet, Christophe ;  Université de Liège - ULiège > GIGA-R : Hématologie
Morschhauser, Franck Andre
Anglaret, Bruno
Soussain, Carole
Fabiani, Bettina
Tilly, Herve
Haioun, Corinne
More authors (10 more) Less
Language :
English
Title :
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Publication date :
2013
Journal title :
Annals of Oncology
ISSN :
0923-7534
eISSN :
1569-8041
Publisher :
Oxford University Press, London, United Kingdom
Volume :
24/n°4
Pages :
1032-1037
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 07 March 2013

Statistics


Number of views
149 (15 by ULiège)
Number of downloads
182 (8 by ULiège)

Scopus citations®
 
27
Scopus citations®
without self-citations
14
OpenCitations
 
28

Bibliography


Similar publications



Contact ORBi